Sequel Med Tech and Senseonics Expand Diabetes Management Options with twiist-Eversense 365 Integration
Event summary
- Sequel Med Tech and Senseonics launched full U.S. availability of the twiist Automated Insulin Delivery (AID) System integrated with the Eversense 365 CGM system on February 19, 2026.
- Eversense 365 is the world’s only one-year CGM, offering uninterrupted glucose monitoring and high accuracy in low glucose ranges.
- twiist is the first AID system compatible with Eversense 365, providing users with more flexibility and choice in diabetes management.
- The integration is now being used in real-world care settings and is broadly available for people with type 1 diabetes in the U.S.
The big picture
The integration of twiist and Eversense 365 represents a significant advancement in diabetes management technology, addressing the need for longer-lasting, more accurate CGM systems. This partnership aligns with the broader industry trend toward personalized and automated diabetes care solutions, potentially setting a new standard for CGM and AID system compatibility. The move could also intensify competition among medical technology companies to offer more comprehensive and user-friendly diabetes management tools.
What we're watching
- Market Adoption
- How quickly the twiist-Eversense 365 combination will be adopted by the diabetes community and healthcare providers.
- Competitive Dynamics
- Whether this integration will pressure competitors like Abbott to enhance their own CGM and AID system offerings.
- Regulatory Compliance
- The pace at which regulatory approvals for similar integrations might accelerate, given the success of this partnership.
Related topics